Project

Go Back to Project List
#16016 : Oncolytic viruses infection
Topics: Transcriptomics (Illumina)
Origin: RIIP
Project type: Service

Name of Applicant: Michela Muscolini
Date of application: 17-11-2022
Unit: Other
Location: Istituto Pasteur Italia – Fondazione Cenci Bolognetti – Rome, Italy
Phone: +390649255676
@ Mail: michela.muscolini@istitutopasteur.it
@ PI-Mail: j.hiscott@istitutopasteuritalia.it

Project context and summary:

Oncolytic virotherapy is a promising anticancer strategy, based on the use of oncolytic viruses (OVs) that selectively infect and kill cancer cells without affecting normal cells. However, the effectiveness of oncolytic virotherapy is restricted by the intrinsic tumor cell resistance to OV infection. A deeper understanding of the mechanisms responsible for tumor resistance to oncolytic virotherapy would represent a critical advance for the development of new therapeutic approaches combining OV vectors with other therapeutics.


Related team publications:
Muscolini M, Hiscott, J, Tassone, E (2023). A Genome-Wide CRISPR-Cas9 Loss-of-Function Screening to Identify Host Restriction Factors Modulating Oncolytic Virotherapy. In: HDAC/HAT Function Assessment and Inhibitor Development. Methods in Molecular Biology, vol 2589: 379-399. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-2788-4_25
Muscolini M, Castiello L, Palermo E, Zevini A, Ferrari M, Olagnier D, and J Hiscott. SIRT1 modulates the sensitivity of prostate cancer cells to VSV oncolysis. J Virol (2019) 93: e00626-19. doi: 10.1128/JVI.00626-19.
Service Delivery
Manager: marc.monot@pasteur.fr
Status: Closed


Go Back to Project List